DOWNERS GROVE, Ill., April 20, 2026 /PRNewswire/ — CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processing, today announced the launch of the AseptiQuik® G PPSU HT Series connectors. The new connectors deliver enhanced versatility in bioprocesses involving high temperatures and harsh chemicals.

The latest addition to the AseptiQuik G line of sterile connectors is BPA-free and made of durable, lightweight polyphenylsulfone (PPSU), which is compatible with both gamma and autoclave sterilization.

PPSU can also withstand a wide pH range from 2 to 12, along with exposure to chemicals such as sodium hydroxide (NaOH), benzyl alcohol, and dimethyl sulfoxide (DMSO). Many of these chemicals are commonly used in downstream processes, including chromatography, column storage, filtration, and purification. PPSU offers significantly greater chemical compatibility than traditional polymers used in single-use biopharma processing equipment.

“Bioprocessors require robust components that offer broader chemical compatibility across the pH scale, along with the flexibility to support both gamma and autoclave sterilization,” said Laura Schweitz, Product Manager, CPC Biotech. “The new AseptiQuik G PPSU HT connectors meet these performance needs and work seamlessly with previous generations of AseptiQuik G products.”

A gold-colored tab distinguishes the new PPSU HT connectors from earlier AseptiQuik polycarbonate (blue or white tabs) and PPSU (purple tab) products. The connectors function consistently with other AseptiQuik connectors, requiring no additional operator training.

“AseptiQuik products enable quick, easy, and sterile connections, even in non-sterile environments,” said Schweitz. “Operators can use the latest product with confidence, knowing it is designed to perform across a broader range of chemicals and withstand the higher temperatures required for autoclaving (266°F/130°C).”

The AseptiQuik G PPSU HT connectors are available in sizes to fit hose barbs of 1/4″, 3/8″, 1/2″, and 3/4″, as well as 3/4″ sanitary fittings.

For more information about the AseptiQuik G PPSU HT Series, please visit https://www.cpc-bio.com/productdetails.AQG17106HT.

About CPC Biotech:

CPC Biotech is at the forefront of bioprocessing fluid management and flow control, offering a comprehensive portfolio of critical components: connectors, pumps, flow meters and sensors. Our industry-leading products permit biopharma innovators to produce next-generation biologics and therapeutics with optimal integrity, yield, efficiency and scalability. From lab to commercial launch, we enable those who drive breakthroughs in medicines and biologics that transform lives and advance humanity. CPC Biotech is part of Pump Solutions Group (PSG), an operating company within Dover Corporation. To learn more about CPC Biotech, please visit cpc-bio.com.

About PSG:

PSG is the global pump, metering and dispensing-solution expert, enabling the safe and efficient transfer of critical and valuable fluids that require optimal performance and reliability in applications where it matters most. Additionally, PSG is a leading provider of flow meters designed to reduce waste and downtime while accurately measuring, monitoring and controlling the distribution of fluids. Headquartered in Downers Grove, IL, USA, PSG is comprised of several world-class brands, including Abaque, All-Flo, Almatec, Blackmer, CPC Biotech, Cryo-Mach, Ebsray, em-tec, Griswold, Hydro, ipp, Malema, Mouvex, Neptune, Quantex, Quattroflow, and Wilden. PSG products are manufactured on three continents – North America, Europe and Asia – in state-of-the-art facilities that practice lean manufacturing and are ISO-certified. PSG is part of the Pumps & Process Solutions segment of Dover Corporation. For additional information on PSG, please visit psgdover.com. PSG: Where Innovation Flows.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 70 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what’s possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under “DOV.” Additional information is available at dovercorporation.com.

PSG Contact:
Christopher Walsh
(331) 277-8137
christopher.walsh@psgdover.com

Dover Media Contact:
Adrian Sakowicz, VP, Communications
(630) 743-5039
asakowicz@dovercorp.com

Dover Investor Contact:
Jack Dickens, VP, Investor Relations
(630) 743-2566
jdickens@dovercorp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cpc-biotech-launches-versatile-aseptiquik-g-connector-302747459.html

SOURCE Dover

Veteran chief ethics and compliance officer, big four consultant, and educator to lead the organization as risk and compliance leaders navigate an increasingly volatile and faster-changing era

GREENWICH, CT, April 20, 2026 /PRNewswire-PRWeb/ — The Ethics and Compliance Initiative and Compliance Week (ECI Compliance Week), both part of Verdian Insights, today announced the appointment of Maurice L. Crescenzi, Jr. as President, effective May 1, 2026. Joining from Moody’s Corporation, Crescenzi will oversee the ECI Compliance Week businesses, which, together, form the cornerstone of Verdian’s trusted ecosystem for enterprise risk. Crescenzi will report to James Lindstrom, CEO of Verdian Insights.

With a diverse and dynamic career that spans more than three decades, Crescenzi previously held senior ethics and compliance leadership roles within the Altria family of companies, Schering-Plough Pharmaceuticals, and the DeVry Education Group. He has also led the ethics and compliance consulting practices at KPMG, Grant Thornton, and FTI Consulting. And for nearly two decades, Crescenzi has served as a graduate-level adjunct professor teaching business ethics and compliance courses at Rutgers University and Montclair State University.

Crescenzi’s appointment positions ECI Compliance Week to accelerate its strategic priorities across news and intelligence, research, benchmarking, credentialing, events, and membership, including the continued expansion of the HQP benchmarking platform and LPEC professional credentialing program. With Crescenzi leading ECI Compliance Week, Verdian will accelerate its investment in strategic partnerships, new products, and AI governance leadership for the ethics and compliance profession.

“Maurice brings a rare combination of leadership-level practitioner experience, commercial discipline, and genuine standing across the profession,” said Lindstrom. “With his strong leadership style, deep subject-matter knowledge, and professional network, he is exactly the leader to evolve our trusted ecosystem and expand our global reach.”

“I have been part of the Compliance Week and ECI communities for decades, seeing firsthand the role these trusted organizations play in shaping global ethics and compliance discourse and in helping practitioners enhance their approach to managing risk, ethics, and compliance,” said Crescenzi. “I am thrilled to help lead this organization into its next chapter as the world’s pre-eminent platform for news and intelligence, research, benchmarking, credentialing, events, and membership.”

Crescenzi will make his first public appearance as President of ECI Compliance Week at Compliance Week National 2026, where he will join industry leaders on the main stage. The conference takes place May 6 to 8 at The Mayflower Hotel in Washington, D.C.

About ECI and Compliance Week

ECI and Compliance Week serve corporate compliance, ethics, legal, audit, and risk professionals globally through research, benchmarking, credentialing, media, and live programming. Learn more at complianceweek.com and eci-insights.com.

Media Contact

James Lindstrom, Verdian Insights, 1 (617) 297-8409, james@complianceweek.com, www.verdianinsights.com 

View original content:https://www.prweb.com/releases/the-ethics-and-compliance-initiative-and-compliance-week-name-maurice-l-crescenzi-jr-president-of-combined-business-302746756.html

SOURCE Verdian Insights

MILFORD, Mass., April 20, 2026 /PRNewswire/ — Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time.

About Waters Corporation

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.

Caspar Tudor, Head of Investor Relations
investor_relations@waters.com

View original content:https://www.prnewswire.co.uk/news-releases/waters-corporation-schedules-first-quarter-2026-earnings-conference-call-302747645.html